United States
Precede Biosciences, founded in 2021, is at the forefront of precision medicine with its innovative first-in-class liquid biopsy platform. With headquarters in the United States, the company stands out for its commitment to enhance the medical community's understanding of disease-defining biology, offering a simple blood test to uncover vital transcriptional biology insights.
The platform uniquely profiles circulating chromatin and the DNA methylome, providing genome-wide data that yields insights into the dynamic activities of genes and pathways from just 1mL of plasma. This breakthrough has significant implications for the development of new medicines and minimalist diagnosis methods that are precise to individual patient biology.
In January 2026, Precede Biosciences secured a $63.50M Debt Financing investment. The round attracted prominent investors, including Lilly Asia Ventures, 5AM Ventures, Illumina Ventures, and Osage University Partners, demonstrating their confidence in Precede's potential to revolutionize precision medicine.
